

## Regimen Reference Order – GENU – enzalutamide

ARIA: GENU – [enzalutamide]

**Planned Course:** Once daily until disease progression or unacceptable toxicity (1 cycle = 30 days)

**Indication for Use:** Prostate Cancer, Metastatic and Non-metastatic Castration-Resistant

OR

Prostate Cancer, Metastatic Castration-Sensitive

### **Proceed with treatment if:**

**ANC equal to or greater than  $1 \times 10^9/L$  AND Platelets equal to or greater than  $50 \times 10^9/L$**

❖ **Contact Physician if parameters not met**

## SEQUENCE OF MEDICATION ADMINISTRATION

### Treatment Regimen – GENU – enzalutamide

Drug	Dose	CCMB Administration Guideline
enzalutamide	160 mg	Orally once daily with or without food Swallow whole (Self-administered at home)
enzalutamide (Xtandi®) available dosage strength: 40 mg capsule Classification: Non-Cytotoxic, Hazardous		

## REQUIRED MONITORING

### Baseline

- CBC, serum creatinine, electrolytes, liver enzymes, testosterone and PSA as per Physician Orders
- Blood pressure
- EKG for patients on anti-arrhythmics at physician's discretion
- Bone density at physician's discretion

### Month 2 and 3

- CBC, serum creatinine, electrolytes, liver enzymes, testosterone and PSA as per Physician Orders
- Blood pressure at each clinic visit

### Subsequent clinic visits (every 3 months)

- CBC, serum creatinine, electrolytes, liver enzymes, testosterone and PSA as per Physician Orders
- Blood pressure at each clinic visit (patients can also monitor at home)

### Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
None required		

---

## INSTRUCTIONS FOR PATIENT

---

- Inform patient to report rash or uncontrolled diarrhea
- Prescriber should be notified of blood pressure measurements greater than 160/95 mmHg
- enzalutamide has potential for drug-drug interactions. Patients should notify clinic prior to starting any new medication
- Avoid grapefruit and grapefruit juice, Seville oranges (i.e. orange marmalade) and starfruit

---

## ADDITIONAL INFORMATION

---

- Androgen Deprivation Therapy (ADT) (e.g. goserelin, leuprolide, degarelix) is continued lifelong throughout treatment course/lines of systemic therapy for prostate cancer
- Patients are at increased fracture risk
- enzalutamide can cause hypertension
- enzalutamide can prolong QT interval
- enzalutamide has been associated with seizures and mental impairment